Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Daniel Drozd

Advertisement

Articles by Daniel Drozd

24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)

ByKathryn Martin,Hope Rugo, MD,Gregory Vidal, MD, PhD,Nina Oestreicher,Deepa Lalla,Gillian Hanson,Daniel Drozd,Kristie Traverso,Dan DiPrimeo,Debu Tripathy, MD
April 18th 2022
Advertisement

Latest Updated Articles

  • 24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)
    24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)

    April 18th 2022



Advertisement
Advertisement

Trending on CancerNetwork

1

Concomitant COVID-19 Vaccination Tied to Improved OS with Immunotherapy

2

FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC

3

Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma

4

Exercise Regimens Could Disrupt Accelerated Cellular Aging in Cancer

5

Sacituzumab Tirumotecan Meets PFS End Point as 1L Option in Advanced TNBC

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us